Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer

Front Endocrinol (Lausanne). 2023 Mar 20:14:1148412. doi: 10.3389/fendo.2023.1148412. eCollection 2023.

Abstract

Colon cancer is the fourth leading cause of cancer death worldwide, and its progression is accompanied by a complex array of genetic variations. CRISPR/Cas9 can identify new drug-resistant or sensitive mutations in colon cancer, and can use gene editing technology to develop new therapeutic targets and provide personalized treatments, thereby significantly improving the treatment of colon cancer patients. CRISPR/Cas9 systems are driving advances in biotechnology. RNA-directed Cas enzymes have accelerated the pace of basic research and led to clinical breakthroughs. This article reviews the rapid development of CRISPR/Cas in colon cancer, from gene editing to transcription regulation, gene knockout, genome-wide CRISPR tools, therapeutic targets, stem cell genomics, immunotherapy, metabolism-related genes and inflammatory bowel disease. In addition, the limitations and future development of CRISPR/Cas9 in colon cancer studies are reviewed. In conclusion, this article reviews the application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer.

Keywords: CRISPR tools; Genetic tool; basic research; colorectal carcinoma; genome editing.

Publication types

  • Review

MeSH terms

  • CRISPR-Cas Systems
  • Colonic Neoplasms*
  • Gene Editing*
  • Gene Expression Regulation
  • Humans
  • Technology